The case in front of me: oxidation · 30 °C.
This is one of those things that everyone repeats and nobody derives.
This matters practically, not just academically, because it changes what I would do next.
What is the causal chain, and where does it stop being established?
Because temperature enters the rate constant through an exponential, so equal steps in temperature multiply the rate instead of adding to it. Arrhenius puts the rate proportional to exp(−Ea/RT); the working approximation is a doubling per 10 K, which takes 5, 15, 25 and 35 °C to multipliers of 1, 2, 4 and 8. The steps in temperature are equal and the steps in rate are not, and that is the whole of the observation. At 30 °C the same rule gives about 5.7 times the refrigerated rate, and another 10 K would roughly double it again. Met and Trp take up oxygen sixteen daltons at a time, and the oxidised species is more polar, so on a reversed-phase column it elutes ahead of the parent rather than behind it. Ea differs by route, so the ranking of routes changes with temperature too — which is why accelerated data extrapolates badly and why nobody should read a 40 °C study as a fast version of a 5 °C one.
Start with the sequence, because which pathways are available depends on which residues are present.
Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.
Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.
Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.
Sequence determines which pathways apply, so general statements are general.
Swirl, never shake. Aggregation is a handling problem more than a time problem.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThis is answerable from the chemistry rather than from anecdote, which is unusual and welcome.
Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.
A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.
Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.
Sequence decides which pathways are even available. Check the residues.
edited 29 Sept 2024 by jana_horakova — reworded for clarity after a comment
Asparagine and glutamine are the deamidation risk, and methionine is the oxidation risk.
Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.
Put another way, light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.
Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.
Cold, dry, dark, still. Those four words cover most of the mitigation.
Specifically, aggregation is a physical process and is the one most often caused by handling rather than by time.
Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.
Nothing here is medical advice, and research-use compounds are not approved for human use.
At dilute concentrations, suspect adsorption before you suspect chemistry.
The honest answer is that most reported "degradation" is adsorption and dilution error rather than chemistry.
Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.
Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.
The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.
A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.